Compounds of formula (I):

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds and methods for treating, preventing, and ameliorating at least one of vascular oxidative stress, improve vascular functions and/or reduce hypertension, comprising administering to a subject a compound that targets mitochondrial CypD to inhibit vascular oxidative stress, improve vascular functions and/or reduce hypertension.

Compounds and methods for treating, preventing, and ameliorating at least one of vascular oxidative stress, improve vascular functions and/or reduce hypertension, comprising administering to a subject a compound that targets mitochondrial CypD to inhibit vascular oxidative stress, improve vascular functions and/or reduce hypertension.

Formylpyridine derivatives having FGFR4 inhibitory activities, a preparation method therefor and use thereof are described. In particular, the formylpyridine derivatives have a structure of formula (I), and the definition of each substituent in the formula are described in the description and claims. The series of compounds of the formula (I) have very strong inhibitory effects on FGFR4 kinases and very high selectivity, and can be widely used in the preparation of medicaments for treating cancers, particularly prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, neuroglioblastoma or rhabdomyosarcoma, and prospectively will be further developed to become a new generation of FGFR4 inhibitors. ##STR00001##

The invention related to compounds of formula (I), ##STR00001##
and pharmaceutically acceptable salts thereof, wherein R.sup.1 to R.sup.2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The invention related to compounds of formula (I), ##STR00001##
and pharmaceutically acceptable salts thereof, wherein R.sup.1 to R.sup.2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.

The present disclosure relates to the preparation of pyridine derivatives, such as α-picoline or α-parvoline, and catalysts useful for the selective preparation of such pyridine derivatives. Particularly, the present disclosure relates to the selective preparation of certain pyridine derivative using dealuminated zeolite catalysts.

The present disclosure relates to the preparation of pyridine derivatives, such as α-picoline or α-parvoline, and catalysts useful for the selective preparation of such pyridine derivatives. Particularly, the present disclosure relates to the selective preparation of certain pyridine derivative using dealuminated zeolite catalysts.

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.